Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.

Gastroenterology
Tom HolvoetDanny De Looze

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder associated with intestinal dysbiosis. Given the reported promising results of open-label fecal microbiota transplantation (FMT) therapy in patients with predominant abdominal bloating, we studied efficacy of this treatment in a randomized, placebo-controlled trial. Patients with refractory IBS, defined as failure of ≥3 conventional therapies, were randomly assigned to single-dose nasojejunal administration of donor stools (n = 43) or autologous stools (n = 19) in a double-blind study, performed from December 2015 through October 2017, and were followed up for 1 year. IBS-related symptoms were assessed by using a daily symptom diary to determine general abdominal discomfort, abdominal bloating, abdominal pain, and flatulence on a scale of 1-6. Number of daily bowel movements, consistency of the stools, and abdominal circumference were also recorded. Patients completed the IBS-specific quality of life questionnaire. Primary endpoints were improvement of IBS symptoms and bloating at 12 weeks (response). Secondary endpoints were changes in IBS symptom scores and quality of life. Stool samples were collected for microbiota amplicon sequencing. Open-label retran...Continue Reading

Associated Clinical Trials

Citations

Mar 18, 2021·World Journal of Gastroenterology : WJG·Katia Farias E SilvaHeitor Siffert Pereira de Souza
May 25, 2021·World Journal of Gastroenterology : WJG·Magdy El-SalhyJan Gunnar Hatlebakk
Jun 20, 2021·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Magdy El-SalhyTrygve Hausken
Jun 26, 2021·World Journal of Gastroenterology : WJG·Magdy El-SalhySutep Gonlachanvit
Jul 9, 2021·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Magdy El-SalhyJan Gunnar Hatlebakk
Oct 21, 2021·Journal of Gastroenterology and Hepatology·Joseph J Y Sung, Sunny H Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.